CDNACareDx, Inc.
Services-Medical Laboratories
- Revenue
- $380M
- 14% YoY
- Operating margin
- -8.1%
- 166% YoY
- EBITDA
- −$16M
- 129% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$250M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowFired209% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear19% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $296M | $322M | $280M | $334M | $380M | 14% |
| Operating income | −$30M | −$77M | −$203M | $41M | −$31M | 176% |
| Net income | −$31M | −$77M | −$190M | $53M | −$21M | 141% |
| Operating cash flow | −$19M | −$25M | −$18M | $38M | $42M | 10% |
| Stock-based comp | $36M | $47M | $49M | $66M | $35M | 47% |
| Buybacks | $0 | $642K | $28M | $522K | $88M | 16714% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 26 | 125 |
| FY2024 | — | — | 30 | 93 |
| FY2023 | — | — | 17 | 94 |
| FY2022 | — | — | 16 | 90 |
| FY2021 | — | — | 63 | 100 |